Ortivus AB Stock: price and insider trades · Sweden

This page follows insider dealings at Ortivus AB as filed with Finansinspektionen, a company from the Health Care sector. In the past year (18 October 2025 to 18 October 2026), 16 filings came from 8 insiders.

Only purchases show up on the open market, 9 purchases in all worth €2.1M, filed by 7 insiders. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Among those who bought: 5 board members, 1 finance chief and 1 chief executive. Biggest ticket of the year: €2.0M, bought by Peter Edwall and made public on 15 January 2026 (12.6% of market cap).

Across the 885 companies tracked on its exchange, the median is 7 filings; at 16 filings, this issuer sits above that mark. Our records for Ortivus AB go back to 2021, with 12 purchases and no sales on the open market in total.

The data flag 6 purchases as part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The clock since the last published purchase (15 July 2026) now reads 94 days. Filings reach the Finansinspektionen feed a median of 2 days after the trade. The regulation allows three business days to notify a trade (MAR article 19).

Other companies in the same sector with recent insider buying flagged by our signals: MAIA Biotechnology, Inc. and Cooper Companies, Inc. This summary is built from Finansinspektionen disclosures alone and does not predict where the share price will go.